Although melanoma has a relatively low incidence among malignant tumors, its hidden onset and high malignancy make it a formidable disease. In recent years, targeted and immunotherapy treatments for solid tumors have developed rapidly, many of which began with melanoma and later extended to other cancers. However, there are significant biological differences between melanoma in Chinese and Western patients, necessitating the development of treatment protocols and standards tailored to Chinese and Asian patients. At the 2024 CSCO Conference, Dr. Jun Guo from Peking University Cancer Hospital, Dr. Xiaohui Niu from Beijing Jishuitan Hospital/National Center for Orthopedics, Dr. Di Wu from The First Bethune Hospital of Jilin University, and Dr. Lu Si from Peking University Cancer Hospital shared insights into the journey of melanoma diagnosis and treatment in China. They also reflected on the efforts of the CSCO Melanoma Expert Committee in establishing standardized treatment guidelines tailored to China’s needs.

The 2024 CSCO Ovarian Cancer Session covered various topics, including surgical treatment for ovarian cancer, drug therapy for advanced-stage patients, and data from novel drug research. Dr. Lingying Wu from the Cancer Hospital Chinese Academy of Medical Sciences chaired the session, where Dr. Oliver Dorigo from Stanford University delivered a report on “Cellular Therapy for Ovarian Cancer,” and Dr. Jianyu Rao from University of California, Los Angeles(UCLA) discussed “Precision Treatment Strategies for Ovarian Cancer.” After the session, the three experts participated in Oncology Frontier’s “CSCO International Perspectives” column, engaging in an in-depth discussion on cellular therapy and precision treatment strategies for ovarian cancer.

At the 2024 ESMO Conference, the Phase 1a/1b study of the novel drug GQ1005, led by Dr. Biyun Wang from Fudan University Shanghai Cancer Center, was showcased as a poster presentation, garnering significant attention. This study not only confirmed the efficacy and safety of GQ1005 in HER2-low breast cancer and HER2-positive gastric cancer but also laid a solid foundation for its future clinical applications. We invited Dr. Biyun Wang to delve into the background, study design, preliminary efficacy, and safety data of the GQ1005 Phase 1a/1b study, while also discussing its promising future in combination therapies.

The 2024 European Society for Medical Oncology (ESMO) Congress took place in Barcelona, Spain, from September 13 to 17. During the event, Dr. Miaoyan Wei from Fudan University Shanghai Cancer Center presented the results of an open-label, single-arm, single-center Phase II clinical trial exploring the use of fruquintinib combined with nab-paclitaxel and gemcitabine (AG) as a first-line treatment for liver metastases in pancreatic ductal adenocarcinoma (PDAC). This study was featured in the poster session (Abstract #1529P). In this interview, Dr. Wei provides an in-depth analysis of the study's findings.

The 2024 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), is currently in full swing in San Diego, USA.  Oncology Frontier invited domestic lung cancer experts to analyze key research data from the conference. This article presents Dr. Shengxiang Ren's review of the NeoCOAST-2 study results (Abstract PL02.07) from Shanghai Pulmonary Hospital.

The 2024 European Society for Medical Oncology (ESMO) Annual Congress was held from September 13 to 17 in Barcelona, Spain, where multiple advancements in lung cancer research were presented. Dr. Jonathan D. Spicer from the McGill University Health Centre in Montreal, Canada, shared the updated clinical data from the CheckMate 77T study. During the congress, Oncology Frontier interviewed Professor Spicer, who provided insights on the updated data and discussed how to choose between neoadjuvant therapy, adjuvant therapy, and perioperative strategies in resectable non-small cell lung cancer (NSCLC).

The 2024 World Conference on Lung Cancer (WCLC) recently concluded in San Diego, USA. As one of the largest academic conferences in the field of oncology, WCLC presents the latest cutting-edge advancements, covering all aspects of lung cancer research. Dr. Yilong Wu from Guangdong Provincial People’s Hospital served as an expert chair and delivered a keynote presentation during an educational session, sharing the results of several clinical trials. Oncology Frontier had the privilege of interviewing Professor Wu onsite, where he reflected on his experience attending the 2024 WCLC.

A patient-level analysis of the phase III CheckMate 77T trial (NCT04025879) and the phase III CheckMate 816 trial (NCT02998528) revealed that perioperative treatment with nivolumab for resectable non-small cell lung cancer (NSCLC) patients reduces the risk of disease recurrence or death by approximately 40%, compared to neoadjuvant nivolumab plus chemotherapy alone. This article presents Dr. Yong Song from General Hospital of Eastern Theater Command’s insights on the analysis results (Abstract PL02.07).